Our study is the first network meta-analysis to address the effects of SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors on kidney outcomes in participants with type 2 diabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.